Anthracyclines, such as doxorubicin, are effective chemotherapeutic agents for the treatment
of cancer, but their clinical use is associated with severe and potentially life-threatening …

Cancer diagnostics and therapies have improved steadily over the last few decades,
markedly increasing life expectancy for patients at all ages. However, conventional and …

Chemotherapy with anthracycline-based regimens remains a cornerstone of treatment of
many solid and blood tumors but is associated with a significant risk of cardiotoxicity, which …

Background Many drugs approved for other indications can control the growth of tumor cells
and limit adverse events (AE). Data sources Literature searches with keywords 'repurposing …

Cardiotoxicity is a significant complication of chemotherapeutic agents in cancer patients.
Cardiovascular incidents including LV dysfunction, heart failure (HF), severe arrhythmias …

Exercise training has a profound impact on immunity, exerting a multitude of positive effects
in indications such as immunosenescence, cancer, viral infections and inflammatory …

Background Anthracyclines are a key chemotherapeutic agent used against hematological
and solid organ malignancies. However, their benefits in cancer survival are limited by …

The evolution of cancer treatment and development of new classes of anticancer therapies
have continued to revolutionize the field of oncology. New therapies including targeted …

Abstract Purpose Cardiotoxicity affects 5–16% of cancer patients who receive anthracyclines
and/or trastuzumab. Limited research has examined interventions to mitigate cardiotoxicity …

Nanotechnology has emerged as a promising approach for the targeted delivery of
therapeutic agents while improving their efficacy and safety. As a result, nanomaterial …